Project Grant R01AG092220
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Massachusetts Medical School is focused on understanding how the gut microbiome influences neurodegeneration and protects against Alzheimer's disease. The $647,979 award, effective September 30, 2024 through August 31, 2025, will leverage the C. elegans model system to: Determine how bacterial production of vitamin B12 protects against neurodegeneration pathways. Examine...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $167,940 aims to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease (AD). The key objectives are to: Determine whether the transcription factor MEF2 mediates the survival of specific neuronal subtypes vulnerable to AD pathology. Customized viral vectors will be used to overexpress MEF2A or MEF2C in excitatory or inhibitory neurons in mouse models...
- This $484,314 Project Grant was awarded by the National Science Foundation (NSF) Division of Integrative Organismal Systems under the Biological Sciences program (CFDA 47.074). The funding will support research at Christopher Newport University to investigate the "microbiota-gut-brain axis" and the impact of intestinal barrier dysfunction on aging and neurodegeneration. Key objectives include gaining insights into the cellular and molecular changes associated with an aging gut, how...
- This is a Project Grant award from the National Institute on Aging's (NIA) Aging Research Federal Grant Program (CFDA 93.866) in the amount of $856,580 with a start date of February 1, 2025 and an ultimate completion date of January 31, 2030. The grant aims to elucidate the role of the gut microbiome in Alzheimer's disease and related dementias (AD/ADRD) among the Latino population. The key products and services to be delivered under this grant include: Generating longitudinal gut microbiome...
- This Project Grant award of $952,090 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a randomized, double-blind clinical trial to test the safety and feasibility of a custom probiotic intervention among people with Alzheimer's disease (AD) dementia and preclinical AD. The study will enroll participants from the Wisconsin Alzheimer's Disease Research Center and evaluate secondary outcomes related to cognitive function, plasma biomarkers, and potential mechanisms by...
- This Project Grant awarded by the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to investigate how the gut microbiome composition impacts gastrointestinal (GI) and central nervous system (CNS) function in a mouse model of autism spectrum disorder (ASD). The $430,375 award to the partnership between Henry Ford Health and Michigan State University Health Sciences will...
- The University of Alabama at Birmingham (UAB) has been awarded a $1,869,019 Project Grant by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The funding will support a 3-year research project to investigate the role of circadian rhythms, gut microbiome, and gut-to-brain signaling in the onset and progression of Alzheimer's disease (AD) using a Drosophila (fruit fly) model. Key objectives include determining whether depletion of gut microbiota...
- This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
- This National Science Foundation (NSF) Project Grant award to Wake Forest University, under the Computer and Information Science and Engineering (CFDA 47.070) program, aims to develop a "Neuron Twin" computational system that simulates the human brain to improve understanding and predictions related to Alzheimer's disease. The $501,329 five-year project will leverage deep learning and multiscale modeling to jointly analyze multimodal data, including genetic, neuroimaging, and...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Trustees of Boston University, doing business as Boston University Medical Campus, provides $2,330,859.00 in funding to study age-related changes in brain network connectivity and their relationship to cognitive decline. The 3-year project aims to use multimodal neuroimaging, single-cell transcriptomics, electrophysiology, and neural tract-tracing in a rhesus monkey model to delineate how...
CRCNS: REPURPOSING TRANSFORMERS TO CHARACTERIZE GUT MICROBIOME & AGING BRAIN AXIS - FOR DEBILITATING NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD), SOME DRUGS HAVE BEEN APPROVED BUT ONLY OFFER A MODEST ATTENUATION OF COGNITIVE DECLINE. THERE IS A NEED TO BETTER UNDERSTAND THE ROLE OF MODIFIABLE RISK FACTORS WHICH COULD DECREASE THE RISK OF AD AND OTHER TYPES OF DEMENTIA. THE HUMAN GUT MICROBIOME-COMPRISING OF MICROBES AND THEIR ASSOCIATED GENES-SHOWS DIFFERENCES IN COMPOSITION BETWEEN HEALTHY INDIVIDUALS AND THOSE WITH AD DEMENTIA, AND BASED ON RECENT STUDIES APPEARS TO BE A PROMISING MODIFIABLE RISK FACTOR. DESPITE ENCOURAGING FINDINGS, LARGE GAPS REMAIN REGARDING OUR KNOWLEDGE OF THE GUT MICROBIOME'S RELATIONSHIP WITH THE AGING BRAIN AND DEMENTIA PATHOLOGY MEASURED VIA NEUROIMAGING, FLUID BIOMARKERS, AND COGNITIVE ASSESSMENTS. FORTUNATELY, DATASETS THAT CAN ENABLE THIS ANALYSIS ARE GROWING IN TERMS OF SAMPLE SIZES, MAKING A COMPREHENSIVE MACHINE-LEARNING BASED INVESTIGATION OF THESE ASSOCIATIONS TIMELY AND POTENTIALLY HIGHLY REWARDING. TO THIS END, OUR TEAM PROPOSES TO MAKE USE OF AND EXTEND CONTEMPORARY DEVELOPMENTS IN TRANSFORMER-BASED MODELS THAT POWER ADVANCEMENTS IN LARGE LANGUAGE MODEL (LLM) TECHNOLOGIES, AND REPURPOSE THEM INTO SPECIALIZED MODELS FOR THESE ANALYSES FOR MULTI-MODAL DATASETS. THE KEY COMPONENTS OF THIS PROJECT INCLUDE THE FOLLOWING AIMS. AIM 1: WE WILL DESIGN SPECIAL TRANSFORMER-BASED MODELS THAT WILL BE TRAINED USING MICROBIOME DATA VIA ATTACHING NOVEL TRAINABLE MODULES. THESE REPURPOSED MODELS WILL ENABLE ANALYSIS OF ASSOCIATIONS BETWEEN GUT MICROBIOME COMPOSITION AND BRAIN HEALTH IN DEMENTIA. AIM 2: OUR MODELS WILL BE EXTENDED TO HANDLE 3D NEUROIMAGING DATA WITH AN EYE ON COMPUTATIONAL EFFICIENCY. THE MODELS WILL BE RIGOROUSLY EVALUATED ON LARGE IMAGING DATASETS AS WELL AS ON MULTI-MODAL DATASETS. THEIR PERFORMANCE/GENERALIZATION BEHAVIOR WILL BE PROFILED. AIM 3: THE MODELS WILL BE USED TO STUDY THE RELATIONSHIP BETWEEN THE GUT MICROBIOME AND THE BRAIN, ANCHORED BY EIGHT SPECIFIC SCIENTIFIC HYPOTHESES. PRETRAINED MODELS AND SOFTWARE TOOLS WILL BE DISSEMINATED TO THE COMMUNITY. SIGNIFICANCE: THIS PROJECT WILL YIELD SOPHISTICATED METHODS FOR MULTIMODAL ANALYSIS OF MICROBIOME, BRAIN IMAGING AND CLINICAL/COGNITIVE DATA FOR AGING AND ALZHEIMER'S DISEASE. THESE TOOLS WILL BE DISSEMINATED AND CAN BE USED TO INVESTIGATE A VARIETY OF SCIENTIFIC HYPOTHESES TO DETERMINE NOVEL RELATIONSHIPS BETWEEN THE MICROBIOME AND THE BRAIN. THIS IN TURN IS EXPECTED TO OPEN NEW AVENUES FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASE AND IMPROVE THE HEALTH AND WELL-BEING OF AGING AMERICANS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $362.4k | 5/22/25 | ||
| Not listed | $369.9k | 8/16/24 | ||
| Not listed | $369.9k | 8/16/24 |